[Pneumococcal surface protein A and new approaches for pneumococcal vaccine development].
The problem of pneumococcal infections is pressing for the whole world. Existing vaccines based only on pneumococci polysaccharide antigens or polysaccharide antigens and diphtherial anatoxin are not capable of protecting from all serotypes of the microorganism. Reasonability of creation of pneumococcal vaccine based on surface proteins of Streptococcus pneumoniae is discussed in the literature. One of such key pneumococcal proteins is pneumococcal surface protein A (PSPA), because it is detected in all the S. pneumoniae strains, has cross activity and switches B-cell immune response to T-cell. Currently the development of conjugated vaccine based on surface proteins and capsule polysaccharides of pneumococcus seems promising.
D S
DS
Vorob'ev
I B
IB
Semenova
D001402:B-Lymphocytes / Q000276:immunology; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D015195:Drug Design; D006801:Humans; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000737:chemistry; D011135:Polysaccharides, Bacterial / Q000737:chemistry / Q000276:immunology; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage* / Q000737:chemistry
D001426:Bacterial Proteins; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D011994:Recombinant Proteins; D018074:Vaccines, Conjugate; C051592:pneumococcal surface protein A